DataM Blog

DataM resources that are widely useful for your reference. We have curated special links for you to browse through

blog categories

Food and Beverage Healthcare Agriculture Chemicals and Materials Information & Communications Technology Electronics & Semiconductor Energy and Power Automotive and Aviation Consumer Goods Others

AstraZeneca/Daiichi Sankyo vs Pfizer vs Roche: Who Builds the Next ADC Franchise?

The antibody-drug conjugates market is no longer a contest to develop one successful cancer therapy. AstraZeneca–Daiichi Sankyo, Pfizer and Roche are competing to build repeatable franchises spanning multiple targets, tumor types, biomarkers, payloads and treatment settings.

August 14, 2026

The Next Patent Cliff: Which Therapeutic Areas Face the Greatest Revenue Replacement Pressure?

The global pharmaceutical industry is approaching a major patent cliff, with an estimated US$139 billion in revenue at risk through 2030. Oncology, cardiovascular medicine and immunology are expected to face the greatest revenue replacement pressure as blockbuster therapies lose exclusivity. This analysis examines which therapeutic areas are most exposed, how biosimilars are accelerating market shifts, and why companies are investing heavily in late-stage pipelines, obesity therapeutics and next-generation immunology assets to offset future revenue losses.

August 11, 2026

Pills vs Injections: The New Battle for the GLP-1 Market

DataM Intelligence examines Wegovy pill, Foundayo and injectable obesity drugs, covering efficacy, access, pricing, maintenance, M&A and investor impact.

August 10, 2026

Investment Opportunities in Smart Hospitals: Why Healthcare Technology Companies Are Expanding Digital Solutions

The global healthcare industry is entering a new era of digital transformation, with smart hospitals emerging as a major investment opportunity for technology companies, healthcare providers, and investors. Driven by artificial intelligence (AI), Internet of Things (IoT), cloud computing, automation, and connected healthcare infrastructure, smart hospitals are reshaping patient care delivery and hospital operations.

August 6, 2026

Actinium-225 Supply Chain Expansion Signals the Next Phase of Precision Oncology

Growing demand for targeted alpha therapy is driving major investments in Actinium-225 production capacity. New isotope manufacturing facilities are strengthening the radiopharmaceutical supply chain and supporting the future of precision cancer treatments.

July 21, 2026

Top MASH Drug Companies in 2026: Madrigal, Novo Nordisk, Boehringer Ingelheim, Akero, and 89bio Shape the Treatment Landscape

The MASH treatment landscape has entered a new commercial phase following the approval of the first liver-directed therapy. This competitive analysis examines Madrigal Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim, Akero, 89bio, Inventiva and other companies competing through THR-β, GLP-1, FGF21 and fibrosis-focused treatment strategies.

July 13, 2026